Beyond its role in immunity, complement mediates a wide range of functions in the context of morphogenetic or tissue remodeling processes. Angiogenesis is crucial during tissue remodeling in multiple pathologies, however, the knowledge about the regulation of neovascularization by the complement components is scarce. Here we studied the involvement of complement in pathological angiogenesis. Strikingly, we found that mice deficient in the central complement component C3 displayed increased neovascularization in the model of retinopathy of prematurity (ROP) and in the in vivo Matrigel plug assay. In addition, antibody-mediated blockade of C5, treatment with C5aR antagonist, or C5aR-deficiency in mice resulted in enhanced pathologic retina angiogenesis. While complement did not directly affect angiogenesis-related endothelial cell functions, we found that macrophages mediated the anti-angiogenic activity of complement. In particular, C5a-stimulated macrophages were polarized towards an angiogenesis-inhibitory phenotype, including the upregulated secretion of the antiangiogenic soluble VEGF receptor-1. Consistently, macrophage depletion in vivo reversed the increased neovascularization associated with C3-or C5aR-deficiency.
Introduction
The complement system represents a major component of immunity and host defense to infection bridging the innate with the adaptive immune response. It consists of serum proteins, membrane-bound receptors, and regulatory proteins 1 . Upon activation of the complement cascade, the formation of C3 convertases C4bC2a and C3bBb results in the cleavage of the central complement component C3 to C3b and C3a. Deposition of C3b on cell surfaces is important for opsonization and phagocytosis. The released anaphylatoxin C3a as well as C5a that derives from C5 cleavage trigger further immune reactions upon binding to their cellular receptors (C3aR, C5aR, C5L2) 1;2 . The conversion of C3 can be triggered by three distinct pathways, the classical, alternative and lectin pathways 1 . However, C3 or C5 can also be cleaved by proteases that are abundant in inflamed or injured tissues 1;3 . Besides the well-established actions of complement in the elimination of pathogens, the complement system has been recently implicated in a variety of pathophysiological processes, such as ischemia/reperfusion injury, sepsis, autoimmune and inflammatory disorders 1;2;4 . Moreover, recent studies have demonstrated that complement components, through their inflammatory or novel non-inflammatory functions, contribute substantially to and modulate several complex tissue remodeling processes relevant to tissue development or regeneration, including liver regeneration or synapse elimination in the CNS system, whereas C5 facilitates remyelination and prevents gliosis in experimental autoimmune encephalomyelitis [5] [6] [7] [8] .
Angiogenesis is crucial to multiple malignant or inflammatory pathologies and to vision-threatening proliferative retinopathies, such as diabetic retinopathy or retinopathy of prematurity 9 . The hallmark of vasoproliferative retinopathies is exuberant neovascularization that is triggered by retina ischemia/hypoxia, which is the result of For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From retina vessel regression 10 . Inflammatory cells or the innate immunity have been implicated as regulators of pathological angiogenesis 11 , including proliferative retinopathies 12 , and can exert both pro-angiogenic and anti-angiogenic actions. For instance, the impact of macrophage subpopulations on angiogenesis may differ substantially. Dependent on the environmental stimuli, macrophages can obtain a proangiogenic or an anti-angiogenic signature 13;14 .
Previous studies addressing the influence of complement on neovascularization have revealed contradictory results. For instance, a pro-angiogenic function of complement component has been implicated in the model of laser-induced choroidal neovascularization, which represents a model for angiogenesis during the wet form of age-related macular degeneration (AMD). A hallmark of this disease is subretinal drusen formation, where deposits of complement components have been detected, as assessed by proteomic analysis [15] [16] [17] [18] . Moreover, complement factor H and factor B polymorphisms have been associated with neovascular AMD 19 . In contrast, another study suggested that complement may act in an anti-angiogenic fashion in the context of placental dysfunction in a mouse model of spontaneous miscarriage and intrauterine growth restriction 20 . Importantly, the mechanistic insights in regards to the crosstalk between the complement system and neovascularization remain largely unclear. These observations have prompted us to investigate the role of the complement system in postnatal neovascularization by engaging the disease model of proliferative retinopathy of prematurity and the in vivo Matrigel angiogenesis model. By engaging mice deficient in different components of the complement system, we unexpectedly found that complement and the C5a/C5aR axis in particular, can exert anti-angiogenic activity.
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Material and Methods

Reagents
Recombinant mouse GM-CSF was obtained from Endogen (Rockford, IL).
Allophycocyanin (APC)-conjugated antibody against mouse CD11b (clone M1/70) was from BD Biosciences (San Jose, CA). ELISA kits for mouse and human soluble VEGF receptor-1 were from R&D Systems (Minneapolis, MN). RPMI medium, fetal bovine serum (FBS), Trizol and 7-aminoactinomycin D (7-AAD) were from Invitrogen/Gibco (Carlsbad, CA). To deplete macrophages in vivo, clodronate liposomes or empty control liposomes were used (Encapsula NanoSciences, Nashville, TN). Matrigel and growth factor-reduced Matrigel were bought from Becton Dickinson Labware (Bedford, MA).
FITC conjugated Griffonia simplicifolia isolectin-FITC and blocking goat serum were bought from Sigma (St. Louis, MO). For immunodepletion of soluble VEGFR-1 from human monocyte supernatants we used a polyclonal goat anti-human VEGFR-1 antibody (Calbiochem) or goat IgG as control (AbD Serotec). Human C3a peptide agonist NYITELRRQHARASHLGLAR-COOH and human C5a peptide agonist (YSFKPMPLaR), which can interact with their respective mouse receptors, were synthesized using Fmoc-based solid phase synthesis as previously described [21] [22] [23] . C3a
and C5a peptide agonists will be referred to throughout the paper as C3a and C5a, respectively. C5aR antagonist AcF [OPdChaWR] , which has been shown to specifically block C5a-mediated effects in various rodent disease models 5;24 , and control C5aR antagonist AcF[OPdChaAdR] were previously described 25 . The monoclonal antibody BB5.1 against C5 was used to block C5 and terminal complement activation (C5a and C5b-9 generation) and has been previously described 26 . Rat antibody to mouse C3b, background) were used, which had been described before
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. C57BL/6 mice were also purchased from Jackson Laboratories. Briefly, 7-day-old (p7) mice were exposed to 75% oxygen for 5 days in an incubator (BioSpherix, Redfield, NY) with their nursing mother.
At p12, mice were returned to room air. Mice were sacrificed at p17, and eyes were processed for quantification of epiretinal neovascular nuclei
30
. Briefly, 6-µm paraffinembedded sections were stained with periodic acid-Schiff (PAS) and hematoxylin, and 10 intact sections of equal length, each 18 µm apart, were evaluated. All retinal vascular cell nuclei anterior to the internal limiting membrane were counted in each section. The mean of the 10 counted sections represented the average neovascular nuclei per section per eye.
In some experiments, pups were treated with daily intraperitoneal injections of 
Immunofluorescence analysis
Pups were subjected to the ROP model. The eyes of 17-day old pups were enucleated and immersed in 4% paraformaldehyde. After a 24 h fixation, the eyes were frozen and well of a 6-well plate in RPMI, 0.1% FBS) were treated with vehicle control or C5a (100 nM) and supernatants were collected after 4h and 12h. The supernatant was subjected to analysis of human sVEGFR1 content by ELISA (R&D Systems).
HUVEC and HUVEC media were purchased from Cambrex and cultivated as described before 30 . All endothelial cells were used in low passages. HUVEC were grown on culture dishes precoated with 0.2% gelatin (Sigma-Aldrich).
Cell proliferation
Endothelial cell proliferation was determined by measuring total cell number. Briefly, HUVECs (5x10 3 / well) were plated onto 96-well plates and incubated for 6 h in full medium, after which cells were washed once with PBS and the medium was changed, and cells were incubated in endothelial basal medium containing 0.1% fetal bovine
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From serum (FBS, Gibco), or in full endothelial growth medium for 72 h, after which cells were quantified.
In vitro Matrigel tube formation assay
HUVECs (2x10 5 ) were plated on Matrigel-coated tissue culture plates (MatTek, Ashland, MA) in endothelial culture medium containing 10%FBS. Additionally, PBS, C3a (100 nM) or C5a (100 nM) was added to the medium as indicated in figure legends and cells were incubated for 6 h.
In another set of experiments, HUVECs (2x10 5 ) were plated on growth factorreduced Matrigel-coated tissue culture plates (MatTek, Ashland, MA) in endothelial culture medium containing 0.2% FBS, supplemented with VEGF 25ng/ml. Additionally, the supernatant of human monocytes that were pretreated with vehicle control or C5a (100 nM) obtained as described above was added to the wells. In other experiments, human sVEGFR1 was immunodepleted from the supernatant of human monocytes as previously described 35 . After 6h wells were imaged by phase-contrast microscopy 
Real-Time Reverse transcriptase-PCR
Preparation of RNA, cDNA and analysis was basically performed as described before 36 .
Total RNA was isolated from mouse retinas or from non-stimulated (vehicle control) or For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From stimulated (C5a 100 nM for 4h) primary bone marrow-derived mouse macrophages using the RNAeasy RNA extraction kit (Qiagen) with DNase I treatment (Ambion, Austin, Tx) following the manufacturer's instructions. To generate cDNA, total RNA (500 ng) was converted into cDNA using random primers and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA).
The cDNA samples were subsequently subjected to real-time PCR amplification using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) and a QuantiTect SYBR Green PCR kit (Qiagen). For HPRT a primer mix and 30 s at 72°C. Dissociation curve analysis was performed on all PCR products to ensure that specific PCR products were generated. PCR reactions for each product were performed in duplicate and data were analyzed using the comparative C T method as described before 36;37 .
In vivo Matrigel plug assay
The Matrigel assay was generally performed as described previously 30 . Two aliquots of Matrigel (0.5 ml, containing heparin, 10 μg/ml) supplemented with VEGF (200 ng/ml) were injected subcutaneously into the mid-abdominal region of mice. In some experiments, 6 h and 3 d after matigel implantation, C57BL/6 WT mice were injected with control IgG or anti-C5 (clone BB5.1, 750 μg per mouse), whereas in other experiments, 6 h after matigel implantation, mice were injected with control liposomes or clodronate liposomes (Encapsula NanoSciences, Nashville, TN) to deplete macrophages. After 7 days, the mice were sacrificed and the Matrigel plugs were fixed with 4% PFA, processed for histology (frozen sections) and stained with H&E staining 
Data presentation and statistics
Comparisons between group means were performed using Student t-test or MannWhitney U-Test, as appropriate. P<0.05 was considered as statistically significant.
Results
C3 deficiency in mice results in increased postnatal angiogenesis
To address the role of the complement system in neovascularization, we engaged the model of retinopathy of prematurity (ROP) 28;30 . In the ROP model, high oxygen (75%)-induced obliteration of the developing retina vessels in pups between postnatal day 7 and 12 leads to retinal hypoxia after postnatal day 12 when the pups are returned to normoxia. The subsequent hypoxia-driven pro-angiogenic response culminates in pathological excessive neovascularization 28;30 . In the retinas of wild type (WT) mice that were subjected to the ROP model, C3 deposition in vessels was observed by immunostaining (supplemental Fig. 1 ). As expected, the staining for C3 deposition was negative in mice deficient in C3 (supplemental Fig. 1 ). Then we assessed the role of complement in retina neovascularization functionally by comparing WT and C3-/-mice in the ROP model. In contrast to our initial prediction that the pro-inflammatory complement system would act in a pro-angiogenic direction, we found that the absence of a central component of the complement cascade, C3, resulted in significantly increased pathological retina neovascularization on day 17. In particular, the number of epiretinal pathological neovascular nuclei was significantly increased by approximately 1.7-fold in C3-deficient mice as compared to WT mice, as assessed by histological analysis of retina cross-sections (Fig 1A, B) .
The C5a-C5aR axis inhibits pathological retina angiogenesis
The findings with C3-/-mice pointed to a potential anti-angiogenic action of components of the complement system downstream of C3. To provide further evidence for this hypothesis, we assessed neovascularization in mice deficient in the receptors for the For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From active components generated upon C3 cleavage, C3a and C5a. Mice deficient in the receptor for C5a (C5aR) displayed a significant increase in pathological retina angiogenesis, as compared to WT mice. Mice deficient in the receptor for C3a (C3aR)
showed an increase in pathological retina neovascularization, however the effect of C3aR deficiency was not significant ( Fig. 2A and 2B ). Representative histological analysis demonstrating higher neovascularization in C5aR-/-mice is shown in Fig. 2C .
Consistent with a role of C5aR in pathologic retina angiogenesis, C5aR expression was found upregulated in the retinas from mice subjected to the ROP model as compared to retinas of mice kept in normal room air (supplemental Fig. 2 ).
C5a can be generated in C3-/-mice 3 . Therefore, to reconcile the findings from the C3-/-mice with the findings from the C5aR-/-mice, we tested the effect of functional C5 deficiency in the ROP model. To do so, we engaged a functional blockade of C5 and of terminal complement activation by the antibody BB5.1 26 . C5 blockade resulted in a significant upregulation of neovascularization in the ROP model (Fig. 3A) . In order to further substantiate the findings of increased angiogenesis due to the absence of C3 or compared to mice that received a scrambled control peptide (Fig. 3B) . A slighter nonsignificant increase in retina angiogenesis was observed in mice treated every 36 h with postnatal day 12 to day 16 resulted in a significant reduction in pathological retina neovascularization (Fig. 3C ). In addition, C5a or C3a treatment reduced the increased angiogenesis observed in C3-deficient mice (supplemental Fig. 3 ). Taken together, these findings from mice deficient in components of the complement cascade or upon C5 or C5aR blockade, as well as upon C5a treatment suggest that the C5a-C5aR axis acts to inhibit pathological hypoxia-driven retina neovascularization.
Macrophages mediate the anti-angiogenic effect of complement components.
The findings so far suggested an anti-angiogenic effect of the complement system and We then analyzed whether monocytes / macrophages might mediate the antiangiogenic effect of C5a, since (i), inflammatory cells and particularly macrophages have been implicated to be capable of regulating neovascularization in both a positive and a negative fashion 13;14;39 , and (ii), as assessed by real-time PCR analysis, we found that postnatal day p15 retinas from mice subjected to the ROP model had increased levels of the monocyte/macrophage marker CD11b, as compared to retinas from mice that were kept in room air since birth (data not shown), whereas the message for lymphoid markers CD4 and CD8 was not altered due to the ROP manipulation (data not shown). In other words, monocytes/macrophages are increasingly abundant in the retina , we found that C5a stimulated bone marrow derived macrophages displayed increased levels of sVEGFR1 mRNA as well as increased secretion of this anti-angiogenic factor into their supernatant ( Fig. 4A and 4B ). Soluble VEGFR1 is a product of alternative splicing of VEGFR-1 and contains the ligand-binding domain but lacks the cytoplasmic and transmembrane domains and it is thereby an inhibitor of VEGF 42 . Consistent with the regulation of sVEGFR1 expression by complement, the mRNA levels of sVEGFR1 were reduced in the retinas of C3-/-mice that were subjected to the ROP protocol, as compared to WT mice subjected to ROP (data not shown). In addition, active C5a up-regulated the secretion of sVEGFR1 from human peripheral blood isolated monocytes (supplemental Fig. 5) . Accordingly, the supernatant from C5a-stimulated but not of C3a-stimulated human monocytes inhibited
the VEGF-induced capillary-like sprout formation of HUVEC (Fig. 4C) , suggesting that the supernatant of C5a-stimulated monocytes intervenes with the effects of the VEGF system on pro-angiogenic endothelial cell functions. To directly demonstrate that the anti-angiogenic activity of the supernatant of C5a-treated monocytes was mediated by sVEGFR1, we immuno-depleted sVEGFR1 from the monocyte supernatant. Efficient immuno-depletion of sVEGFR1 was confirmed by ELISA analysis of the supernatant (supplemental figure 6A) . Whereas sVEGFR1-containing supernatant from C5a-stimulated monocytes (control Ig-immuno-depletion) significantly inhibited endothelial capillary-like sprout formation, the inhibitory effect of the monocyte supernatant was completely reversed upon sVEGFR1 immuno-depletion (supplemental figure 6B) .
Together, these findings indicate that complement stimulated macrophages are polarized to an angiogenesis inhibitory phenotype including the upregulation of the antiangiogenic sVEGFR1.
We then sought to provide definitive in vivo evidence for the role of myeloid cells/macrophages in mediating the anti-angiogenic effect of complement. To do so, we investigated the effect of macrophage depletion by clodronate liposomes 43 on pathological retina angiogenesis in WT and C3-/-mice. WT or C3-/-pups that were subjected to the ROP model received a single injection of clodronate or control liposomes on postnatal day p13. Flow cytometry analysis of the spleen revealed that efficient depletion of CD11b + cells was achieved (supplemental Fig. 7 ). Macrophage depletion reversed the increased neovascularization in the ROP model due to C3-deficiency. In particular, upon treatment with clodronate liposomes C3-/-mice no longer displayed higher angiogenesis as compared to WT mice (Fig. 5 ). In conclusion, the 
An inhibitory role of complement in VEGF-induced Matrigel angiogenesis in vivo
Our findings so far have pointed to a clear neovascularization inhibitory action of complement and in particular C5a, mediated by macrophages in the disease model of vasoproliferative retinopathy. We then went on to address whether the anti-angiogenic effect of complement could be observed in a less complex in vivo angiogenesis assay.
For this purpose we studied angiogenesis directly induced by VEGF in Matrigel plugs that were implanted into mice. By assessing Matrigel angiogenesis, we found that C3-/-mice had significantly higher levels of new vessel formation as compared to WT mice ( Fig. 6A and B) . Similarly, antibody blockade of C5 (clone BB5.1) or C5aR-deficiency resulted in significantly higher angiogenesis in the Matrigel plug model (Fig. 7A and 7B ).
In accordance with the findings from the ROP model, the pro-angiogenic effect of C3-or C5aR-deficiency was mediated by macrophages. Systemic depletion of macrophages by clodronate liposomes reversed the higher levels of Matrigel angiogenesis in C3-/-or C5aR-/-mice, i.e. no difference was observed in Matrigel angiogenesis between WT and C3-/-mice or WT and C5aR-/-mice that were treated with clodronate liposomes (Fig. 6A and 7C). Taken together, C3 deficiency and C5aR deficiency are associated with increased angiogenesis in the Matrigel plug assay and macrophages are mediators of the pro-angiogenic phenotype of C3-and C5aR-deficiency. For 
Discussion
We here demonstrated that the complement system is a negative regulator of pathological neovascularization in the context of vasoproliferative retinopathy. C3-deficient and C5aR-deficient mice revealed increased pathological retina angiogenesis.
Consistently, antibody blockade of C5 or C5aR antagonism increased and active C5a inhibited pathological retina angiogenesis. Interestingly, the same pro-angiogenic phenotype of complement deficiency was observed in VEGF-induced angiogenesis in the Matrigel plug assay in vivo. The angiogenesis inhibitory effect of complement was not mediated by a direct anti-angiogenic effect of complement components on endothelial cells. In contrast, we found that macrophages acted as the mediators of the anti-angiogenic actions of complement and of C5a in particular. C5a polarized macrophages to a pro-inflammatory phenotype with increased expression of IL-6 and TNF-α and decreased expression of IL-10, which is recognized as the anti-angiogenic macrophage signature 14 . In addition, monocytes/macrophages exposed to C5a in vitro secreted increased amounts of sVEGFR1, which is an established angiogenesis inhibitor 42 . In conclusion, our data make a strong case for an important role of the complement system in antagonizing pathological postnatal angiogenesis.
Our findings provide the first evidence that the complement system may exert an anti-angiogenic action in the course of pathological postnatal neovascularization in the retina. However, our present findings from the less complex growth factor-triggered Matrigel angiogenesis assay in vivo imply that the herein described angiogenesis inhibitory function of complement may not necessarily be restricted to the retina but may extend to other tissues and other forms of postnatal and pathological neovascularization. That complement and C5a can polarize macrophages to the M1 pro-inflammatory phenotype inducing secretion of inflammatory cytokines has been implicated in previous reports 1; [45] [46] [47] and it is increasingly recognized that this macrophage phenotype is associated with anti-angiogenic activity 14;48 . Consistently, we demonstrated here that the anti-angiogenic action of complement was attributed to the presence of macrophages, as macrophage depletion reversed the pro-angiogenic phenotype of C3 deficiency. Thus, the complement-mediated inhibition of neovascularization in a manner dependent on macrophages may represent a previously not described substantial antiangiogenic mechanism.
How does this hypothesis reconcile with the pro-angiogenic actions of complement components reported in models of choroidal neovascularization 15;16;49 ?
Whereas complement may polarize macrophages to an anti-angiogenic phenotype and this may be a predominant action of complement in some cases, such as in proliferative retinopathy, as described here, in the context of choroidal neovascularization this action of complement may be overridden by the complement-mediated induction of the proangiogenic VEGF in retina pigment epithelial cells 16;50 . The retina pigment epithelium plays a unique role in the pathomechanism of choroidal neovascularization (CNV) in the course of age-related macula degeneration 51;52 , whereas these cells are not at all involved in the proliferative retinopathy of prematurity. In addition, intrinsic differences
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From between choroidal and retinal neovascularization may contribute to the opposite actions of the complement system in these two vasoproliferative eye pathologies. A major insight from the present study is that the use of complement inhibitors in age-related macular degeneration, which is at present tested in clinical studies 53 , requires caution and prior understanding of the underlying pathophysiological role of complement, since our findings imply that inhibition of complement might aggravate proliferative diabetic retinopathy 10 , an eye pathology that may be co-prevalent with age-related macular degeneration in some patients. Together, the versatility of functions of the complement system make it imperative that the different actions of complement are studied in detail and understood in different tissues/organs and experimental models of disease.
Although the findings in our work point to a role of C5aR mediating the antiangiogenic effects of C5a, it cannot be excluded that the second C5a receptor C5L2 C5aR-/-mice displayed more neovascular tufts. Scale bars: 150 µM. 
Matrigel neovascularization (% of control)
